Transcranial Magnetic Stimulators Market Size, Share and Global Trend By Type (Single or paired-pulse transcranial magnetic stimulation, Repetitive transcranial magnetic stimulation), By Application (Diagnostics and Research, Therapeutics), and Regional Forecast, 2024-2032

Transcranial magnetic stimulation (TMS) is a neurostimulation technique, which uses a magnetic field to generate electric current. The generated electric current flows through the targeted region through electromagnetic induction technique. A coil is placed on the scalp and connected to the pulse generator that delivers electric current to the coil.

Transcranial magnetic stimulation (TMS) is mainly used to calculate the connection between the central nervous system and skeletal muscles to evaluate damage in various disease conditions including stroke, amyotrophic lateral sclerosis, movement disorders, and others. In August 2018, U.S. Food and Drug Administration (FDA) approved Brainsway deep transcranial magnetic stimulation system, a device designed to treat patients with the obsessive-compulsive disorder (OCD).

The growth in the number of products in the advanced stages of R&D along with the focus on the treatment of rare diseases is anticipated to drive the growth in the transcranial magnetic stimulators (TMS) market during the forecast period. This combined with increasing number of regulatory approvals for devices is leading to rising adoption of transcranial magnetic stimulators in emerging countries.

However, high cost of diagnostics and treatment, adverse effects such as hypomania, transient cognitive changes, and transient hearing loss are some of the major factors restraining the growth in the global transcranial magnetic stimulators market.

Key Players Covered

Some of the major companies that are present in the global transcranial magnetic stimulators (TMS) market are Brainsway Ltd., MagVenture A/S, Nexstim plc, Axilum Robotics, Neuronetics, Inc., TMS Neuro Solutions and Magstim, and other prominent players.

SEGMENTATION

In 2018, repetitive transcranial magnetic stimulation (rTMS) system accounted for the largest share of the global transcranial magnetic stimulators market due to the rise in a number of clinical studies demonstrating the efficiency of the technique in the treatment of psychiatric disorders.

Key Insights

• Pipeline analysis, Key Players
• Regulatory Scenario, Key Countries
• Reimbursement Scenario, Key Countries
• Key Mergers and Acquisitions
• Pricing Analysis, Key Players, 2018
• Prevalence of Key Neurological Disorders, Key Countries/ Region, 2018

Regional Analysis

North America accounted for a significant of the global transcranial magnetic stimulators market in 2018, due to large patient pool suffering from depression and other neurological disorders. This combined with increase in the number of devices receiving regulatory approvals, the rise in demand for advanced stimulators, and reimbursement policies are driving the growth of the market in North America. Europe and the Asia Pacific regions are anticipated to have significant growth in the forecast period due to increase in the physiological disorders, adoption of new and developed transcranial magnetic stimulators available in the market, and development in the healthcare infrastructure.

Key Industry Developments

• In February 2019, Axium Robotics, received European and U.S. regulatory approvals for TMS-Cobot TS MV, a robotic arm specifically developed to position the treatment coil of the MagVenture TMS system.
• In December 2018, Xenon Pharmaceuticals Inc., announced positive results from its XEN1101 Phase 1 clinical trial and the related transcranial magnetic stimulation (TMS) studies.
• In October 2018, MindfulTMS Neurocare, received U.S. FDA approval for its transcranial magnetic stimulation (TMS) device for treating depression, addiction and obsessive compulsive disorders in India.